Empowered Patient Podcast

Ilana Golant, Founder and CEO of the Food Allergy Fund, discusses the increasing prevalence and complexity of food allergies in people of all ages and the lack of research, funding, and diagnostics in this field. The Food Allergy Fund is taking a multifaceted approach to address these challenges, including funding microbiome research, exploring drug repurposing, and leveraging AI to develop better diagnostic tools. The goal is to find a cure for food allergies to prevent life-threatening anaphylaxis and drive research into the connection between food allergies and gut and immune health.

Ilana explains, "We launched a microbiome research collective recently because we really think the microbiome is the common denominator for many diseases. I mean, food allergy really no longer exists in isolation. It used to be 20 years ago, you would say someone had a peanut allergy. That patient doesn't really exist anymore. It is estimated that 40% of patients who have food allergies also have asthma, which is a significant comorbidity, but their other diseases overlap with Crohn's, juvenile diabetes, and atopic dermatitis, among others."

"We really think of food allergy as the canary in the coal mine for lifelong gut and immune health, and what the microbiome dysregulation could mean not only for food allergy, but for broader gut health. And so as part of our Microbiome Collective, we're right now funding studies at six different research institutions across the country to try to figure out what this gut dysbiosis means for food allergy and much more."

#FoodAllergyFund #FoodAllergyResearch #FoodAllergyAwareness #Biotech #Immunology #PatientAdvocacy #HealthcareInnovation #FoodAllergy #Microbiome #AIinHealthcare #DrugRepurposing #AllergyResearch #Anaphylaxis #PrecisionMedicine #EmpoweredPatient

foodallergyfund.org

Listen to the podcast here

Ilana Golant, Founder and CEO of the Food Allergy Fund, discusses the increasing prevalence and complexity of food allergies in people of all ages and the lack of research, funding, and diagnostics in this field. The Food Allergy Fund is taking a multifaceted approach to address these challenges, including funding microbiome research, exploring drug repurposing, and leveraging AI to develop better diagnostic tools. The goal is to find a cure for food allergies to prevent life-threatening anaphylaxis and drive research into the connection between food allergies and gut and immune health.

Ilana explains, "We launched a microbiome research collective recently because we really think the microbiome is the common denominator for many diseases. I mean, food allergy really no longer exists in isolation. It used to be 20 years ago, you would say someone had a peanut allergy. That patient doesn't really exist anymore. It is estimated that 40% of patients who have food allergies also have asthma, which is a significant comorbidity, but their other diseases overlap with Crohn's, juvenile diabetes, and atopic dermatitis, among others."

"We really think of food allergy as the canary in the coal mine for lifelong gut and immune health, and what the microbiome dysregulation could mean not only for food allergy, but for broader gut health. And so as part of our Microbiome Collective, we're right now funding studies at six different research institutions across the country to try to figure out what this gut dysbiosis means for food allergy and much more."

#FoodAllergyFund #FoodAllergyResearch #FoodAllergyAwareness #Biotech #Immunology #PatientAdvocacy #HealthcareInnovation #FoodAllergy #Microbiome #AIinHealthcare #DrugRepurposing #AllergyResearch #Anaphylaxis #PrecisionMedicine #EmpoweredPatient

foodallergyfund.org

Download the transcript here

Talia Cohen Solal, CEO and Co-Founder of NeuroKaire, is focused on improving patient outcomes of those with depression by predicting the most effective antidepressant for each individual. The NeuroKaire platform personalizes psychiatric treatment by creating neurons from a patient's blood sample to model their brain and test drug responses, pointing the way to an effective treatment, avoiding prolonged trial-and-error. This is a significant advancement over existing pharmacogenomic tests, which primarily provide information on drug metabolism rather than drug efficacy. This technology is also being applied to other conditions like ADHD, schizophrenia, bipolar disorder, and epilepsy.

Talia explains, "At NeuroKaire, we are dedicated to improving patient outcomes in psychiatry and neurology. To do that, we've developed a platform to predict which antidepressant is best for each patient and are expanding out to other disease indications to achieve that mission."

"Basically, around 2006, Yamanaka and his colleagues discovered that you could take any cell in the body and turn it back into a stem cell. And that changed everything for the field. So what we can do now is we can take a blood sample, turn it back into a stem cell, and then turn it into whatever cell type we'd like. And our mission is to help people with brain disorders and psychiatric disorders. And so we turn those stem cells into neurons. And now we have a model of the patient's brain. Now we have neurons from the patient's brain and a little ecosystem mimicking a patient's brain. And there we can actually see what's going wrong in the connectivity, what's changed in those patients, and what drugs are going to have the best outcome to reverse those changes."

#NeuroKaire #PrecisionPsychiatry #MentalHealth #Antidepressants #BrightKaire #PersonalizedMedicine #PGx #Neuroscience #HealthcareInnovation

neurokaire.com

Listen to the podcast here

Talia Cohen Solal, CEO and Co-Founder of NeuroKaire, is focused on improving patient outcomes of those with depression by predicting the most effective antidepressant for each individual. The NeuroKaire platform personalizes psychiatric treatment by creating neurons from a patient's blood sample to model their brain and test drug responses, pointing the way to an effective treatment, avoiding prolonged trial-and-error. This is a significant advancement over existing pharmacogenomic tests, which primarily provide information on drug metabolism rather than drug efficacy. This technology is also being applied to other conditions like ADHD, schizophrenia, bipolar disorder, and epilepsy.

Talia explains, "At NeuroKaire, we are dedicated to improving patient outcomes in psychiatry and neurology. To do that, we've developed a platform to predict which antidepressant is best for each patient and are expanding out to other disease indications to achieve that mission."

"Basically, around 2006, Yamanaka and his colleagues discovered that you could take any cell in the body and turn it back into a stem cell. And that changed everything for the field. So what we can do now is we can take a blood sample, turn it back into a stem cell, and then turn it into whatever cell type we'd like. And our mission is to help people with brain disorders and psychiatric disorders. And so we turn those stem cells into neurons. And now we have a model of the patient's brain. Now we have neurons from the patient's brain and a little ecosystem mimicking a patient's brain. And there we can actually see what's going wrong in the connectivity, what's changed in those patients, and what drugs are going to have the best outcome to reverse those changes."

#NeuroKaire #PrecisionPsychiatry #MentalHealth #Antidepressants #BrightKaire #PersonalizedMedicine #PGx #Neuroscience #HealthcareInnovation

neurokaire.com

Download the transcript here

Todd Van Meter, CEO of Accuity, highlights the evolution of the revenue cycle from simple billing and coding to include data analytics to reduce friction and prevent revenue leakage. Accuity specializes in reviewing inpatient accounts before billing, using a combination of AI and physicians to ensure claims are compliant and accurate. Getting the clinical analysis and coding correct initially significantly reduces costly, time-consuming clinical denials.

Todd explains, Revenue cycle is a term that's really become more relevant here, in the last maybe decade plus. Years ago, it used to be called billing and coding and a whole different bunch of terms. And really, it's this whole idea of how, when a patient's going through their care event, how are you tracking them from when they access care all the way through documenting their care to coding the care they received and then getting a bill out to an insurance company or to a patient to get reimbursed for the care they received. And so the transformation has been going on for a long time."

"The cost has been pretty well identified over the years. From a cost perspective, the goal is to perform all of this work as cost-effectively as possible, and faster is better for patients and for hospitals in terms of processing accounts, cash flow, and other financial metrics. So I think what I've seen happening for health systems is that the data is allowing for better visibility, back to your cost point, into where there are opportunities to take out friction, to do things better, faster, cheaper, to process accounts. And to take care of patients better, and communicate better to both patients and insurance companies, and internally, just from a tracking perspective, and to make sure, to your other point, that there's really not any leakage all along the way."

#Accuity #Healthcare #RevenueCycleManagement #RCM #Hospitals #InpatientCare #MedicalAI #HumanintheLoop

accuityhealthcare.com

Listen to the podcast here

Todd Van Meter, CEO of Accuity, highlights the evolution of the revenue cycle from simple billing and coding to include data analytics to reduce friction and prevent revenue leakage. Accuity specializes in reviewing inpatient accounts before billing, using a combination of AI and physicians to ensure claims are compliant and accurate. Getting the clinical analysis and coding correct initially significantly reduces costly, time-consuming clinical denials.

Todd explains, Revenue cycle is a term that's really become more relevant here, in the last maybe decade plus. Years ago, it used to be called billing and coding and a whole different bunch of terms. And really, it's this whole idea of how, when a patient's going through their care event, how are you tracking them from when they access care all the way through documenting their care to coding the care they received and then getting a bill out to an insurance company or to a patient to get reimbursed for the care they received. And so the transformation has been going on for a long time."

"The cost has been pretty well identified over the years. From a cost perspective, the goal is to perform all of this work as cost-effectively as possible, and faster is better for patients and for hospitals in terms of processing accounts, cash flow, and other financial metrics. So I think what I've seen happening for health systems is that the data is allowing for better visibility, back to your cost point, into where there are opportunities to take out friction, to do things better, faster, cheaper, to process accounts. And to take care of patients better, and communicate better to both patients and insurance companies, and internally, just from a tracking perspective, and to make sure, to your other point, that there's really not any leakage all along the way."

#Accuity #Healthcare #RevenueCycleManagement #RCM #Hospitals #InpatientCare #MedicalAI #HumanintheLoop

accuityhealthcare.com

Download the transcript here

Ewa and Doug Tweedy, and Dr. Nancy M. Young, the Lillian Wells Professor of Pediatric Otolaryngology at the Ann and Robert H. Lurie Children's Hospital in Chicago, come together to discuss bilateral sensorineural hearing loss. Nancy served as the principal investigator for a clinical trial examining the use of MED-EL's cochlear implants in young children with bilateral sensorineural hearing loss. Ewa and Doug's daughter, Ella, was born deaf in both ears and enrolled in the trial at seven months. The procedure and device have demonstrated safety and efficacy in supporting the development of listening and spoken language skills, with some surprising results. The Tweedy family emphasizes the importance of therapy and parental engagement in achieving positive outcomes, noting that Ella is excelling in a mainstream school.

Nancy explains, "Bilateral sensorineural hearing loss is permanent hearing loss. It arises from the inner ear. So we're not talking about temporary hearing loss from, say, fluid in the ear after a routine ear infection. So it usually arises from the inner ear, sometimes from the nerve of hearing. And it's often present at birth in certain children, but it can also have a later onset after birth."

Ewa elaborates, "So, at the hospital right after her birth, we had someone come in to perform the newborn hearing screening, and we had two of those done one day after the next, and she did not pass either one of those. So they tried to tell us it might possibly be the fluid in the ears. So we just remained hopeful. But then, after a couple of weeks, we got her retested, again, and she did not pass. And then we went in for what Dr. Young referred to as the ADR so that diagnostic testing could be done for children. And there we found out that she did have the bilateral, so both sides, profound sensorineural hearing loss. We were told she was completely deaf."

Doug continues, "I've had some passing information about it previously. I definitely was not an expert, definitely had not done the level of investigation and reading that I've done at this point. It was at least a familiarity to me. I do have a technologist background, so technology is something that has always been an interest to me, and cochlear implants are definitely a very unique technology."

#MEDEL #CochlearImplants #Pediatrics #Audiology #ENT #EarlyIntervention #HearingHealth #SensorineuralHearingLoss #NeonatalCare #ChildDevelopment

MEDEL.com

Listen to the podcast here

Ewa and Doug Tweedy, and Dr. Nancy M. Young, the Lillian Wells Professor of Pediatric Otolaryngology at the Ann and Robert H. Lurie Children's Hospital in Chicago, come together to discuss bilateral sensorineural hearing loss. Nancy served as the principal investigator for a clinical trial examining the use of MED-EL's cochlear implants in young children with bilateral sensorineural hearing loss. Ewa and Doug's daughter, Ella, was born deaf in both ears and enrolled in the trial at seven months. The procedure and device have demonstrated safety and efficacy in supporting the development of listening and spoken language skills, with some surprising results. The Tweedy family emphasizes the importance of therapy and parental engagement in achieving positive outcomes, noting that Ella is excelling in a mainstream school.

Nancy explains, "Bilateral sensorineural hearing loss is permanent hearing loss. It arises from the inner ear. So we're not talking about temporary hearing loss from, say, fluid in the ear after a routine ear infection. So it usually arises from the inner ear, sometimes from the nerve of hearing. And it's often present at birth in certain children, but it can also have a later onset after birth."

Ewa elaborates, "So, at the hospital right after her birth, we had someone come in to perform the newborn hearing screening, and we had two of those done one day after the next, and she did not pass either one of those. So they tried to tell us it might possibly be the fluid in the ears. So we just remained hopeful. But then, after a couple of weeks, we got her retested, again, and she did not pass. And then we went in for what Dr. Young referred to as the ADR so that diagnostic testing could be done for children. And there we found out that she did have the bilateral, so both sides, profound sensorineural hearing loss. We were told she was completely deaf."

Doug continues, "I've had some passing information about it previously. I definitely was not an expert, definitely had not done the level of investigation and reading that I've done at this point. It was at least a familiarity to me. I do have a technologist background, so technology is something that has always been an interest to me, and cochlear implants are definitely a very unique technology."

#MEDEL #CochlearImplants #Pediatrics #Audiology #ENT #EarlyIntervention #HearingHealth #SensorineuralHearingLoss #NeonatalCare #ChildDevelopment

MEDEL.com

Download the transcript here

Dr. Julie Chen, Chief Medical Officer at Radence, outlines the use of genomic precision medicine and advanced biomarkers and imaging technology for early detection and diagnosis of disease, with a focus on extending the health span, not just the lifespan, of their clients. This comprehensive membership-based model aggregates members' health data to create a 360° view of their health risks. AI is a critical tool for identifying trends in longitudinal data, enabling more accurate and personalized health monitoring for both those who are healthy and those recovering from an existing condition.

Julie explains, "Our model is a membership-based model primarily because a lot of the leading-edge technology is not insurance-covered. And so we're able to then utilize what is necessary for the diagnosis and the management, and actionable steps for the members, without having to worry about what insurance will or will not cover."

"Our members come through, and we actually aggregate all of their outside medical records and data because we want to see what their baseline health has been up to the point that they join us as a member. And then at that point, we actually get from the cellular level all the way up to the organ level and functionality level, we start to aggregate information about their genomics, so the blueprint of who they are health-wise."

"The key focus here is really looking at the concept that longevity is a larger picture phrase that has been in this industry, used across the board for a lot of different things. That could encompass biohacking, to true evidence-based genomic precision medicine, to just trends of what people are using. So I think it's really important for your listeners to understand that longevity is theoretically in the category of what we're doing in that space, but the very important point is to really look at the space, as there are a lot of things on the market now."

#Radence #GenomicMedicine #PrecisionMedicine #EarlyDetection #HealthSpan #Longevity #AIinHealthcare #PreventiveCare

Radence.com

Listen to the podcast here

Dr. Julie Chen, Chief Medical Officer at Radence, outlines the use of genomic precision medicine and advanced biomarkers and imaging technology for early detection and diagnosis of disease, with a focus on extending the health span, not just the lifespan, of their clients. This comprehensive membership-based model aggregates members' health data to create a 360° view of their health risks. AI is a critical tool for identifying trends in longitudinal data, enabling more accurate and personalized health monitoring for both those who are healthy and those recovering from an existing condition.

Julie explains, "Our model is a membership-based model primarily because a lot of the leading-edge technology is not insurance-covered. And so we're able to then utilize what is necessary for the diagnosis and the management, and actionable steps for the members, without having to worry about what insurance will or will not cover."

"Our members come through, and we actually aggregate all of their outside medical records and data because we want to see what their baseline health has been up to the point that they join us as a member. And then at that point, we actually get from the cellular level all the way up to the organ level and functionality level, we start to aggregate information about their genomics, so the blueprint of who they are health-wise."

"The key focus here is really looking at the concept that longevity is a larger picture phrase that has been in this industry, used across the board for a lot of different things. That could encompass biohacking, to true evidence-based genomic precision medicine, to just trends of what people are using. So I think it's really important for your listeners to understand that longevity is theoretically in the category of what we're doing in that space, but the very important point is to really look at the space, as there are a lot of things on the market now."

#Radence #GenomicMedicine #PrecisionMedicine #EarlyDetection #HealthSpan #Longevity #AIinHealthcare #PreventiveCare

Radence.com

Download the transcript here